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ABSTRACT 
 
Development of a biotechnological process for the 
inhalational administration of a bacteriophage was pursued, 
using strategies of nanoencapsulation within lipid 
nanovesicles. As a proof-of-concept for the 
nanoencapsulation strategy, a bacteriophage with broad 
lytic spectrum was entrapped within W/O/W multiple 
nanoemulsions. Physicochemical characterization of the 
optimized bacteriophage-encasing nanovesicles 
encompassed determination of particle hydrodynamic size, 
size distribution and particle charge via DLS, surface 
morphology via CRYO-SEM, and thermal analysis via 
DSC, whereas antimicrobial activity of the nanoemulsions 
produced was assessed in vitro using several bacterial 
strains. The optimized nanosystems showed no phase 
separation and encompassed nanovesicles with an average 
size of ca. 114 nm and an average Zeta Potential of ca. -13 
mV, which were maintained stable over a storage 
timeframe of ca. 3 months. 
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1 INTRODUCTION 
 
The emergence of antibiotic-resistant bacterial strains 
put an emphasis in the need for safe(r) and effective 
alternatives for antimicrobial treatments. The application of 
strictly lytic bacteriophages (or cocktails therefrom) has 
been proposed as an alternative (or complement) to 
conventional antibiotics, allowing release of the natural 
predators of bacteria directly to the site of infection. 
Probably, the major advantage of bacteriophage-based 
antibiotherapy relative to its chemical counterpart lies in the 
fact that bacteriophages replicate directly at the site of 
infection, becoming profusely available where they are 
most needed, as long as there exists viable hosts. When 
compared to conventional chemical antibiotics, 
bacteriophages present many other relevant advantages: (i) 
strong tissue permeability; (ii) total compatibility (and may 
act synergistically) with chemical antibiotics; and (iii) 
isolation and large-scale production of new lytic 
bacteriophages is much simpler and economical than 
developing a new antibiotic. 
Water-in-oil-in-water (W/O/W) emulsions are examples 
of multiple emulsions, in which dispersions of small water 
droplets within larger oil droplets are themselves dispersed 
in a continuous (outer) aqueous phase [1, 3, 4]. Due to their 
compartimentalized internal structure, multiple emulsions 
present advantages for encapsulation of bioentities, such as 
the ability to carry both polar and non-polar molecules, and 
a better control over releasing of therapeutic molecules [2, 
4, 5]. 
In this research effort, development of a 
biotechnological process for the inhalational administration 
of a bacteriophage was pursued, using strategies of 
nanoencapsulation within lipid nanovesicles. As a proof-of-
concept for the nanoencapsulation strategy, a bacteriophage 
with broad lytic spectrum was entrapped within W/O/W 
multiple nanoemulsions. Physicochemical characterization 
of the optimized bacteriophage-encasing nanovesicles 
encompassed determination of particle hydrodynamic size, 
size distribution and particle charge via DLS, surface 
morphology via CRYO-SEM, and thermal analysis via 
DSC, whereas antimicrobial activity of the nanoemulsions 
produced was assessed in vitro using several bacterial 
strains. 
This method of targeting may have a high potential for 
the treatment of respiratory bacterial infections because the 
aerosol is delivered directly at the site of infection, thereby 
accelerating the action of bacterial predators, whereas 
protection for the bacteriophage against the immune system 
is provided by the lipid nanovesicles. The optimized 
nanosystems showed no phase separation and encompassed 
nanovesicles with an average size of ca. 114 nm and an 
average Zeta Potential of ca. -13 mV, which were 
maintained stable over a storage timeframe of ca. 3 months. 
Compatibility between increased amounts of Tween 80 
and other components of the internal aqueous phase can be 
attributed to hydrogen bonding and to the lower crystalline 
lattice energy of this polymer, which had a notorious impact 
in the melting profile of the optimized nanoemulsion. 
Increasing molecular weight of the lipid (such as in Softisan 
100™) and decreasing dielectric constant (such as in Tween 
80) indicates greater hydrophobicity, leading to a greater 
impregnation of the interface and therefore to a more stable 
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(nano)emulsion, which is in clear agreement with the long-
term stability observed for our multiple nanoemulsion 
systems. 
 
 
2 EXPERIMENTAL METHODS 
 
In the present research work, the potential of 
nanoencapsulating a broad lytic spectrum phage able to 
infect enteric Salmonella and E. coli has been investigated. 
Phage phi-PVP-SE1 was entrapped within W/O/W multiple 
nanoemulsions, aiming at mimicking the multifunctional 
design of biology, with several lipid matrices, poloxamers 
and stabilizing layer compositions. Physicochemical 
characterization of the optimized phage-encasing 
nanovesicle formulations encompassed determination of 
particle size, size distribution and particle charge, via Zeta 
potential analysis, surface morphology via SEM, 
encapsulation efficiency, and thermal analysis via DSC. 
The antimicrobial activity of the nanoemulsions produced 
was also assessed in vitro, using several microbial strains. 
The experimental methodology encompassed three 
phases: (i) Development and optimization of a multiple 
nanoemulsion W/O/W encompassing lipid nanovesicles for 
phage (nano)encapsulation; (ii) Evaluation of stability and 
physicochemical characterization of the formulated and 
optimized multiple nanoemulsion; and (iii) In vitro 
assessment of viability of nanoencapsulated bacteriophages. 
For preparation of the multiple emulsion systems, an oily 
phase (O) was prepared by melting together 0.5 g Softisan 
100™ and 0.05 g lecithin on a thermostatted bath set at ca. 
40 °C and maintained at this temperature. In a separate 
beaker, 5 mL glicerol was heated up to ca. 40 °C in the 
same thermostatted bath. For the internal aqueous phase 
(Win), 5 mL HCl 0.01 M and 0.05 g Tween 80™ were 
heated together up to ca. 40 °C in the same thermostatted 
bath, and added with 5 mg lyophilized bacteriophage. 
When Softisan 100™ and lecithin were melted down, both 
glicerol and 1 mL of Win were added and thoroughly 
mixed with an UltraTurrax IKA T25 for 10 min, set at 
10000 RPM, in the thermostatted bath, thus forming an 
Win/O emulsion. The external aqueous phase (Wext) was 
prepared by dissolving 0.4 g Lutrol F68 in 40 mL water. 20 
mL Wext was heated up in a thermostatted bath set at ca. 40 
°C, added to the Win/O emulsion, and thoroughly mixed 
with the UltraTurrax for 10 min at 10000 RPM. The 
remainder 20 mL of Lutrol was added to the emulsion thus 
produced and homogenized using a magnetic stirrer until 
room temperature. 
 
 
Table 1: Formulation and optimization of the Multiple 
W/O/W nanoemulsion system, with 
bacteriophage Phi-PVP-SE1 encased. 
 
Full physicochemical characterization of the 
nanoemulsion produced proceeded via determination of the 
Zeta Potential, differential scanning calorimetric analysis, 
hydrodynamic size and polydispersion index, SEM and 
Cryo-SEM analysis. 
As a proof-of-concept to test the bacteriophage 
nanoencapsulation procedure, a newly isolated 
bacteriophage (from poultry production sewage water), phi-
PVP-SE1 (2/2) (a broad lytic spectrum phage able to infect 
Salmonella enteric and E. coli) was utilized in all 
nanoencapsulation procedures. Phage 2/2 was produced in a 
Salmonella enteric Enteritidis host, grown in Luria-Bertani 
molten agar. A total volume of 40 mL of SM- buffer 
containing 109 PFU (plaque-forming units) / mL was 
lyophilized, and subsequently utilized in all multiple 
nanoemulsion formulations. Dynamic Laser Scattering 
analysis of an (ultrapure) aqueous suspension of this 
bacteriophage revealed an average particle size of ca. 65.2 
nm. 
Optimized nanoemulsions were assessed for 
antimicrobial (lytic) activity, following a simple laboratory 
procedure: (1) Lipid nanoparticles encasing bacteriophage 
(1000 µL) were added with 20 µL of chloroform in a test 
tube, to extract the encased bacteriophages; (2) The 
resulting suspension was gently vortexed for a short period 
of time (5 s), and was subsequently centrifuged at 9000 x g 
for 10 min; (3) Following centrifugation, (aqueous) 
supernatant was immediately recovered and submitted to 
the “spot” test as follows (4.-7.); (4) 100 µL of bacterial 
suspension (Salmonella enteric Enteritidis) grown overnight 
at 37 °C were added to 3 mL of top-agar; (5) Following a 
gentle homogenization, the top agar added with bacterial 
suspension was poured into a 90 mm Petri dish previously 
prepared with 10 mL bottom-agar and allowed to dry; (6) A 
5 µL drop of the recovered sample supernatant (3.) was 
then applied and allowed to dry; (7) Incubation of the Petri 
dish was then allowed at 37 °C, overnight. 
 
 
3 EXPERIMENTAL RESULTS 
 
 
Figure 1: Changes in nanoparticle Zeta Potential values 
throughout storage time. 
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 Figure 2: Changes in nanoparticle Hydrodynamic Size 
throughout storage time. 
 
 
Figure 3: Thermograms of optimized bacteriophage-
encasing nanoemulsion and plain bacteriophage 
suspension. 
 
 
 
Figure 4: Nanoemulsion structure, with bacteriophage Phi-
PVP-SE1 encased, via CRYO-SEM. 
 
 
Figure 5: Nanovesicles encasing bacteriophage Phi-PVP-
SE1, via CRYO-SEM. 
 
 
4 DISCUSSION AND CONCLUSIONS 
 
Bacteriophage lyophilizate reconstituted in SM-buffer 
displayed lytic activity, as expected. The first 
bacteriophage-encasing nanoemulsions did not exhibit lytic 
activity, probably due to one (or more) of the following: (i) 
low pH in the inner aqueous phase (pH ≈ 2.31)? most 
likely, since the bacteriophage utilized demonstrated to be 
sensitive to a pH value of 2.0 (but not to pH values of 4.0-
5.0); (ii) homogenization stirring speed? not likely, since 
several researchers reported no loss of viability at stirring 
speeds of 14000 rpm. Our procedure encompassed 
homogenization at 10000 rpm; (iii) thermolability of 
bacteriophages? not likely, since the bacteriophage utilized 
in the nanoencapsulation trials thrives in the gastrointestinal 
tract of chickens, where normal temperature reaches ca. 41 
°C (105 °F). The temperature utilized in our 
nanoencapsulation trials was always below 39 °C (melting 
temperature of SOFTISAN 100™ is ca. 35 °C); (iv) low 
bacteriophage concentration? yes, this was most likely the 
cause for not detecting lytic activity of the bacteriophage-
encasing nanoemulsions... New nanoemulsions were 
produced using amounts of bacteriophage 5 and 10 times 
higher, which displayed positive antimicrobial activity. 
Macroscopic observations of optimized nanosystems 
with increased amount of the semicrystalline polymer 
(Tween 80™, i.e. poly(oxyethylene) sorbitan monooleate) 
showed no visible phase separation, and absence of 
adherence to the container walls even after a prolonged 
storage at room temperature. Optimized nanosystem 
encompassed nanovesicles with an average size of ca. 114 
nm and an average Zeta Potential of ca. -13 mV, which 
were maintained stable over a storage timeframe of nearly 3 
months. The sudden increase in particle size after storage at 
room temperature for ca. 3 months was attributable to 
particle aggregation in the nanosuspension. Inclusion of 
Tween 80™ in higher amounts led to a significative 
decrease in the peak temperature (from 88 °C and 
absorption of 0.182 J/mg in departing nanoemulsion to ca. 
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79.2 °C and absorption of 0.509 J/mg in optimized 
counterpart), denoting a widening of the melting profile in 
the optimized nanoemulsion, with an increase in peak area 
of over 64 %. 
Compatibility between increased amounts of Tween 
80™ and other components of internal aqueous phase can 
be attributed to hydrogen bonding and to the lower 
crystalline lattice energy of this polymer, which had a 
notorious impact in the melting profile of the optimized 
nanoemulsion. 
In water-in-oil emulsions (such as our nanovesicles), 
there is a positive correlation between emulsion stability 
and fatty acid chain length and a negative correlation with 
the dielectric constant of the emulsifier. Increasing 
molecular weight (such as in Softisan 100™, with C10-C18 
fatty acid moieties) and decreasing dielectric constant (such 
as in Tween 80™) indicates greater hydrophobicity, leading 
to a greater impregnation of the interface and to a more 
stable (nano)emulsion, which is in clear agreement with the 
long-term stability observed for our multiple nanoemulsion 
systems. 
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